Abstracts tagged "antigens and vasculitis"

Abstract Number: 907 • 2018 ACR/ARHP Annual Meeting
Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Gwen Thompson¹, Marta Casal Moura², Darlene Nelson¹, Amber Hummel¹, Dieter E. Jenne³, Fernando Fervenza⁴, Gary S. Hoffman⁵, Cees G.M. Kallenberg⁶, Carol Langford⁷, Joseph W. McCune⁸, Peter A. Merkel⁹, Paul A. Monach¹⁰, Philip Seo¹¹, Robert F. Spiera¹², Eugene William St. Clair¹³, Steven R. Ytterberg¹⁴, John H. Stone¹⁵, William H. Robinson¹⁶, Yuan-Ping Pang¹ and Ulrich Specks¹⁷, ¹Mayo Clinic, Rochester, MN, ²Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, ³Helmholtz Zentrum München, Munich, Germany, ⁴Nephrology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶University of Gronigen, Groningen, Netherlands, ⁷Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Hospital for Special Surgery, New York, NY, ¹³Medicine, Duke University Medical Center, Durham, NC, ¹⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁶Stanford, Stanford, CA, ¹⁷Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Human-murine chimeric variants have been used to study specific epitope recognition by anti-neutrophil cytoplasmic antibodies (ANCAs) targeting proteinase 3 (PR3) in patients with ANCA-associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].